Trademark: BLUE EARTH 2253477
Word
BLUE EARTH
ID
2253477
Trademark Type
Word
Status
Cancelled: Cancelled at the request of IB
Application Date
02 December 2021
Registration Date
02 December 2021
Cancellation Date
05 January 2023
Owner(s)
Service
Goods and Services:
Class 1:
Alpha- and beta-emitting radionuclides for use in radionuclide therapy; radioactive elements for scientific purposes; synthetic amino acids for use in radionuclide therapy; reagents for use in radionuclide therapy.
Alpha- and beta-emitting radionuclides for use in radionuclide therapy; radioactive elements for scientific purposes; synthetic amino acids for use in radionuclide therapy; reagents for use in radionuclide therapy.
Class 5:
Therapeutic chemicals for medical purposes; chemicals for pharmaceutical use; pharmaceutical drugs; pharmaceutical preparations; pharmaceutical preparations, namely, radiotherapeutic preparations and radiodiagnostic preparations; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical products; radiopharmaceuticals used in the field of nuclear medicine, intended for medical imaging and therapy.
Therapeutic chemicals for medical purposes; chemicals for pharmaceutical use; pharmaceutical drugs; pharmaceutical preparations; pharmaceutical preparations, namely, radiotherapeutic preparations and radiodiagnostic preparations; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical products; radiopharmaceuticals used in the field of nuclear medicine, intended for medical imaging and therapy.
Class 42:
Scientific and medical research and product design in relation to radionuclide therapy; medical and scientific research in relation to disease diagnosis and treatment; scientific and medical research in relation to molecular imaging; development of non-medical molecular imaging services; development of radionuclide therapy products; diagnostic imaging for scientific purposes; scientific imaging services.
Scientific and medical research and product design in relation to radionuclide therapy; medical and scientific research in relation to disease diagnosis and treatment; scientific and medical research in relation to molecular imaging; development of non-medical molecular imaging services; development of radionuclide therapy products; diagnostic imaging for scientific purposes; scientific imaging services.